Antibiotice Sustainability Profile
Antibiotice S.A., a prominent player in the pharmaceutical industry, is headquartered in Iaşi, Romania. Established in 1955, the company has evolved into a leading manufacturer of generic antibiotics and other essential medications, serving both domestic and international markets. With a strong focus on research and development, Antibiotice has achieved significant milestones, including the production of innovative formulations and a robust portfolio of over 200 products. The company’s core offerings include injectable antibiotics, oral medications, and topical treatments, distinguished by their high quality and efficacy. Antibiotice is recognised for its commitment to sustainability and compliance with international standards, positioning itself as a trusted partner in healthcare. With a solid market presence in Europe and beyond, Antibiotice continues to contribute to global health through its dedication to pharmaceutical excellence.
DitchCarbon Score
How does Antibiotice's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Antibiotice's score of 36 is higher than 56% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Antibiotice's reported carbon emissions
In 2024, Antibiotice S.A., headquartered in Romania, reported total carbon emissions of approximately 94,954,410 kg CO2e. This includes Scope 1 emissions of about 9,495,410 kg CO2e, primarily from stationary combustion (approximately 8,620,690 kg CO2e), and Scope 2 emissions of about 3,589,130 kg CO2e (market-based). Notably, their Scope 3 emissions were significantly higher, totalling approximately 73,014,390 kg CO2e, with the largest contributions from purchased goods and services (about 57,818,330 kg CO2e) and capital goods (approximately 11,076,080 kg CO2e). Antibiotice has set ambitious climate commitments, aiming for a 46% reduction in greenhouse gas emissions from their operations (Scope 1 and 2) by 2030, using 2019 as the baseline year. This target reflects their commitment to sustainability within the pharmaceuticals, biotechnology, and life sciences sector. The company is currently classified as "Committed" to near-term targets under the Science Based Targets initiative (SBTi), although they have not yet established a net-zero target. Overall, Antibiotice's emissions data and climate commitments illustrate a proactive approach to reducing their carbon footprint while addressing the challenges of sustainability in the pharmaceutical industry.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2019 | 2020 | 2021 | 2022 | 2024 | |
|---|---|---|---|---|---|
| Scope 1 | 10,417,990 | 00,000,000 | 00,000,000 | 0,000,000 | 0,000,000 |
| Scope 2 | 1,296,330 | - | - | - | 0,000,000 |
| Scope 3 | - | - | - | - | 00,000,000 |
How Carbon Intensive is Antibiotice's Industry?
How Carbon Intensive is Antibiotice's Location?
Antibiotice's Scope 3 Categories Breakdown
The vast majority of their carbon footprint comes from suppliers and value chain emissions, representing the vast majority of total emissions under the GHG Protocol, with "Purchased Goods and Services" being the largest emissions source at 79% of Scope 3 emissions.
Top Scope 3 Categories
Antibiotice's Climate Goals (2030 & 2050)
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
Antibiotice has established climate goals through participation in recognized frameworks and target-setting initiatives. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.
Frequently Asked Questions
Common questions about Antibiotice's sustainability data and climate commitments